Publication: Evaluation of Anti-S1 IgA Response to Different COVID-19 Vaccination Regimens
0
0
Issued Date
2023
Resource Type
File Type
application/pdf
Rights Holder(s)
มหาวิทยาลัยศรีนครินทรวิโรฒ
Bibliographic Citation
Vaccines. Vol 11, No.6 (2023)
Suggested Citation
Bureerug T.C., Kanokudom S., Suntronwong N., Yorsaeng R., Assawakosri S., Thongmee T., Poovorawan Y. Evaluation of Anti-S1 IgA Response to Different COVID-19 Vaccination Regimens. Vaccines. Vol 11, No.6 (2023). doi:10.3390/vaccines11061117 Retrieved from: https://hdl.handle.net/20.500.14740/12452
Other Contributor(s)
Abstract
IgA plays a crucial role in early virus neutralization. To identify the IgA stimulation by COVID-19 vaccine, this study aimed to evaluate the level of anti-S1 IgA in the serum of participants immunized with different COVID-19 vaccination regimens. Sera from 567 eligible participants vaccinated with two, three, or four doses of different types of COVID-19 vaccine were recruited. Post-vaccine anti-S1 IgA responses significantly varied according to vaccine type and regimen. The finding showed that heterologous boosters, especially after priming with an inactivated vaccine, elicited higher IgA levels than homologous boosters. Vaccination with SV/SV/PF produced the highest IgA level among all the immunization regimens after either two, three, or four doses. The different routes and amounts of vaccine used for vaccination showed non-significant differences in IgA levels. After the third dose of immunization for 4 months, the level of IgA decreased significantly from the level found on day 28 in both SV/SV/AZ and SV/SV/PF groups. In conclusion, our study showed that heterologous booster regimens for COVID-19 elicited higher anti-S1 IgA levels in serum, especially after priming with inactivated vaccine. The presented anti-S1 IgA may have advantages in preventing SARS-CoV-2 infection and severe disease. © 2023 by the authors.